Scibase AB (SCIB) - Total Liabilities

Latest as of December 2025: Skr45.51 Million SEK ≈ $4.90 Million USD

Based on the latest financial reports, Scibase AB (SCIB) has total liabilities worth Skr45.51 Million SEK (≈ $4.90 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SCIB net asset momentum to track the company's year-over-year net asset growth rate.

Scibase AB - Total Liabilities Trend (2012–2025)

This chart illustrates how Scibase AB's total liabilities have evolved over time, based on quarterly financial data.

Scibase AB Competitors by Total Liabilities

The table below lists competitors of Scibase AB ranked by their total liabilities.

Company Country Total Liabilities
Mstc Limited
NSE:MSTCLTD
India Rs11.83 Billion
SK Chemicals Co Ltd
KO:285130
Korea ₩2.60 Trillion
Genbyte Technology Inc
SHE:003028
China CN¥981.62 Million
Orange County Bancorp Inc
NASDAQ:OBT
USA $2.38 Billion
GULF KEYSTONE PETR.
F:GVP1
Germany €149.70 Million
Eastern & Oriental Bhd
KLSE:3417
Malaysia RM2.55 Billion
Nextensa NV
BR:NEXTA
Belgium €696.87 Million
Luxfer Holdings PLC
NYSE:LXFR
USA $168.90 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Scibase AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Scibase AB (SCIB) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.92 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.91 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 6.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.87 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scibase AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scibase AB (2012–2025)

The table below shows the annual total liabilities of Scibase AB from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr45.51 Million
≈ $4.90 Million
+81.46%
2024-12-31 Skr25.08 Million
≈ $2.70 Million
+17.87%
2023-12-31 Skr21.28 Million
≈ $2.29 Million
-13.56%
2022-12-31 Skr24.62 Million
≈ $2.65 Million
+67.92%
2021-12-31 Skr14.66 Million
≈ $1.58 Million
+18.31%
2020-12-31 Skr12.39 Million
≈ $1.33 Million
-12.42%
2019-12-31 Skr14.15 Million
≈ $1.52 Million
+46.84%
2018-12-31 Skr9.63 Million
≈ $1.04 Million
-20.95%
2017-12-31 Skr12.19 Million
≈ $1.31 Million
-114.63%
2016-12-31 Skr-83.30 Million
≈ $-8.96 Million
-39.71%
2015-12-31 Skr-138.17 Million
≈ $-14.87 Million
-1641.01%
2014-12-31 Skr8.97 Million
≈ $964.88K
+19.58%
2013-12-31 Skr7.50 Million
≈ $806.90K
-84.23%
2012-12-31 Skr47.56 Million
≈ $5.12 Million
--

About Scibase AB

ST:SCIB Sweden Medical Devices
Market Cap
$3.27 Billion
Skr30.37 Billion SEK
Market Cap Rank
#12492 Global
#202 in Sweden
Share Price
Skr29.70
Change (1 day)
-0.34%
52-Week Range
Skr0.21 - Skr50.80
All Time High
Skr50.80
About

SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more